Format

Send to

Choose Destination
Eur J Pharmacol. 2015 Oct 5;764:306-17. doi: 10.1016/j.ejphar.2015.07.030. Epub 2015 Jul 11.

Different approaches in the treatment of obstructive pulmonary diseases.

Author information

1
Department of Pharmacy, BRAC University, Dhaka, Bangladesh. Electronic address: eva.kabir@gmail.com.
2
Department of Pharmacy, BRAC University, Dhaka, Bangladesh. Electronic address: brishty91@hotmail.com.

Abstract

Advances in drug formulation, inhalation device design and disease management are generating new opportunities for patients suffering from obstructive pulmonary diseases. This article provides a comprehensive review of the different promising pulmonary drug delivery technologies in the treatment of obstructive pulmonary diseases, particularly with regard to the treatment of asthma and chronic pulmonary diseases (COPD), which are increasing day by day due to increasing environmental pollution and its harmful and toxic contaminants. In the recent years, a better knowledge has been gained regarding the mechanism of action of glucocorticoids and how they suppress the chronic inflammation. New etiology has been brought into light regarding the inactivity of glucocorticoids in some patients having asthma and COPDs even though the inflammatory genes are triggered by similar molecules in both the diseases. This new knowledge has given a new platform to improve glucocorticoids and their resistance also how other combination therapy can be used for these diseases. It has also led to the quest for improving and developing other alternatives such as anti-leukotriene agents, muscarinic inhibitors, combination therapy, as well as biologic immune-modulators in the treatment of the different pulmonary diseases. Several new combinations of glucocorticoids are available in the global market for the use in pulmonary diseases especially asthma although their availability fluctuates between continents. There has been several studies done regarding the variation of effectiveness of the different inhaled glucocorticoids and hence it is important to take into consideration the different delivery systems and the methods which are used to treat the patients.

KEYWORDS:

Biologic immunomodulators; Glucocorticoids; Mechanism of action; Obstructive pulmonary disease treatment

PMID:
26172082
DOI:
10.1016/j.ejphar.2015.07.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center